Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325715 · ClinicalTrials.gov registry record · Phase 1
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
NCT00325715 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 150 participants.
The verdict
NCT00325715, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
Study Summary
AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers
Interventions
- DRUG esomeprazole
- DRUG AGN 201904
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325715
The ClinicalTrials.gov registry entry for NCT00325715 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which esomeprazole is the first listed.
NCT00325715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325715 about?
NCT00325715 is a clinical study titled "AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers". AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers
What is the current status of trial NCT00325715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2006-04. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00325715?
The interventions under investigation include: esomeprazole (DRUG), AGN 201904 (DRUG).
Who is sponsoring clinical trial NCT00325715?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.